Environment and pharmaceuticals / Environmentially classified pharmaceuticals / A Alimentary and metabolic

Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2010-06-11

« New search

A Alimentary and metabolic

Substance	Risk	PBT	P	B	T	Volume in DDD	ATC
Stomatological preparations							A01
amphotericin B	cannot be excl	-	-	-	-	40 164	A01A B04 J02A A01
metronidazole	insigni- ficant	4	3	0	1	221 561 E 339 795	A01A B17 D06B X01 G01A F01 J01X D01 P01A B01
triamcinolone	cannot be excl	4 N.B.	3	0	1 N.B.	197 228 E 3 213 285	A01A C01 D01A C20 D07A B09 D07B B03 D07X B02 H02A B08 R01A D11
Drugs for acid related disorders							A02
omeprazole	insigni- ficant	4	3	0	1	20 894 829	A02B C01 A02B D05
cimetidine	insigni- ficant	3	3	0	0	7 850	A02B A01
ranitidine	insigni- ficant	3	3	0	0	1 650 864	A02B A02
esomeprazole	insigni- ficant	4	3	0	1	3 225 849 C 16 786	A02B C05 A02B D06
pantoprazole	insigni- ficant	4	3	0	1	957 874	A02B C02
misoprostol	insigni- ficant	4 N.B.	3 N.B.	0	1	29 005 C 563 750	A02B B01 M01A B55
lansoprazole	cannot be excl	4	3	0	1	1 349 609	A02B C03
rabeprazole	cannot be excl	5 N.B.	3 N.B.	0	2	4 220	A02B C04
Antiemetics and antinauseants							A04
ondansetron	insigni- ficant	6	3	0	1	69 812	A04A A01
granisetron	insigni- ficant	4	3	0	1	13 130	A04A A02
aprepitant	insigni- ficant	9 N.B.	3	3	3 N.B.	1 408	A04A D12
scopolamine	cannot be excl	-	-	0	-	16 310 C 40 093	A04A D01 N02A G01
palonosetron	cannot be excl	-	-	-	-	1 097	A04A A05
tropisetron		9 N.B.	3	3 N.B.	3	4 944	A04A A03
Laxatives							A06
psyllium	none					2 136 284 C 3 785	A06A C01 A06A C51
lactulose	none					7 790 390	A06A D11
karaya gum	none					3 191 248	A06A C03
sodium picosulfate	cannot be excl	5 N.B.	3	0	2 N.B.	1 987 310	A06A B08
lactitol	none						A06A D12
sennoside	none						A06A C51
bisacodyl	cannot be excl	5 N.B.	3	0	2 N.B.	1 500 493	A06A B02 A06A G02
docusate sodium	cannot be excl	8 N.B.	3 N.B.	3	2 N.B.	C 97 490	A06A B57 A06A G10
Antidiarrheals, intestinal anti-inflammatory/anti-infective agents							A07
vancomycin	none					11 783	A07A A09
mesalazine	cannot be excl	6 N.B.	3	0	3 N.B.	1 264 377	A07E C02
loperamide	cannot be excl	8 N.B.	3 N.B.	3	2 N.B.	1 245 786 C 186 093	A07D A03 A07D A05 A07D A53
nystatin	cannot be excl	-	-	-	-	124 702 E 8 460	A07A A02 D01A A01
prednisolone	cannot be excl	-	-	-	-	4 158 325	A07E A01 C05A A04 H02A B06 S01B A04
budesonide	insigni- ficant	8	3	3	2	9 310 580 C 5 564 010	A07E A06 R01A D05 R03A K07 R03B A02
sodium cromoglycate	cannot be excl	3 N.B.	3 N.B.	0	0 N.B.	250 013	A07E B01 R01A C01 R03B C01 S01G X01
olsalazine	cannot be excl	3 N.B.	3 N.B.	0	0	80 013	A07E C03
dimethicone	cannot be excl	-	-	-	-	3 587 506 C 186 093	A03A X13 A07D A53
carbon	cannot be excl	-	-	-	-	48 550	A07B A01
sulfasalazine	cannot be excl	-	-	-	-	840 903	A07E C01
Antiobesity preparations, excluding diet products							A08
orlistat		8	3	3	2	649 264	A08A B01
Drugs used in diabetes							A10
metformin	insigni- ficant	5	3	0	3	8 355 798 C 187 998	A10B A02 A10B D03 A10B D05
glibenclamide	insigni- ficant	5 N.B.	3	0	2 N.B.	2 766 314	A10B B01
glimepiride	insigni- ficant	6 N.B.	3	3 N.B.	0	692 758	A10B B12
glipizide	cannot be excl	4 N.B.	3 N.B.	0	1 N.B.	255 656	A10B B07
repaglinide	cannot be excl	4 N.B.	3	0	1 N.B.	371 693	A10B X02
pioglitazone	cannot be excl	-	-	-	-	149 009 C 1 288	A10B G03
Anabola steroider							A14
nandrolone	cannot be excl	-	-	-	-	7 525	A14A B01